GSK Articles
Pfizer lures GSK exec to head medicines development unit; completes tender offer for King Pharma
1 February 2011
Disappointments as Actelion and GSK discontinue almorexant in sleep disorder and Sanofi’s iniparib fails in Ph III
28 January 2011
US FDA issues a CRL for GlaxoSmithKline’s sNDA on Avodart for prostate cancer risk reduction
28 January 2011
GlaxoSmithKline starts two Ph III metastatic melanoma studies; benefits for early price cuts in Philippines
25 January 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
European Commission launches second monitoring purge of patent settlements in pharma sector
18 January 2011
Orexo licenses Abstral to Invida for in Asia Pacific: GlaxoSmithKline gets rights to bilastine in Spain and Poland
17 January 2011
France’s Immutep signs deal worth up to $100 million with GlaxoSmithKline for ImmuTune IMP731
7 January 2011
UK’s NICE backs GlaxoSmithKline’s Votrient for the first-line treatment of advanced RCC
24 December 2010
Public Citizen says Pharma is biggest defrauder of US federal government under False Claims Act
20 December 2010
More NICE rejections, for Roche’s Avastin and Herceptin and GlaxoSmithKline’s Tyverb
15 December 2010
Zacks analysts view GlaxoSmithKline’s recent acquisition spree, but CEO sees slow down in M&A
15 December 2010
Australia’s fight against cancer continues with new additions to the PBS, says health minister
10 December 2010
US FDA panel negative on extending GSK’s Avodart and Merck & Co’s Proscar use; Agency delays ezogabine
2 December 2010
Shanghai Pharma to acquire majority stake in China Health System for up to $600 million: GlaxoSmithKline on China hunt?
2 December 2010
Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK
2 December 2010
GlaxoSmithKline to invest £500 million in UK after tax promise; faces questions on Avodart benefits
30 November 2010
GlaxoSmithKline ups stake in Theravance to 19%, buying additional shares for $129.4 million
30 November 2010
Amarin will apply for approval of cholesterol drug candidate AMR101 earlier on strong Ph III results
30 November 2010
GlaxoSmithKline sells US penicillin facility and products to India’s Dr Reddy’s; GSK favored in Paxil trial
24 November 2010
GlaxoSmithKline and Human Genome see shares rise after getting US FDA advisory panel backing for lupus drug Benlysta
17 November 2010
GlaxoSmithKline and Human Genome fall as US FDA questions lupus drug candidate Benlysta
15 November 2010
Another foray into neglected diseases as GlaxoSmithKline extends partnership with Brazil’s Fiocruz
15 November 2010
Former GlaxoSmithKline lawyer charged with obstruction and making false statements in USA
10 November 2010
GlaxoSmithKline and XenoPort respond to FDA on Horizant for RLS; Pozen gets positive advisory recommendation on GI drug
8 November 2010
Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016
3 November 2010
GlaxoSmithKline in $230 million deal with Amicus for global rights to Ph III Fabry disease drug Amigal
1 November 2010
GlaxoSmithKline takes $750 million charge to settle with US DoJ regarding former Puerto Rico plant
27 October 2010
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
GlaxoSmithKline 3rd-qtr 2010 profits weighed down by Avandia ban, flu vaccines and charges
22 October 2010
GlaxoSmithKline in R&D pact with two Italian groups for rare genetic disorders; outlines rare disease strategy
19 October 2010
Experts and patient groups highlight urgent need for improvement in the management of osteoporosis in the UK
13 October 2010
Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals
7 October 2010
Robust uptake of Amgen/GlaxoSmithKline's Prolia for the treatment of osteoporosis projected
1 October 2010
Arixtra cleared in EU for superficial vein thrombosis
30 September 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
Double whammy for GlaxoSmithKline, as European regulator suspends Avandia and US FDA further restricts use of the diabetes drug
24 September 2010
Europe’s CHMP gives negative opinion for Merck KGaA’ cladribine in multiple sclerosis; backs Sanofi Pasteur MSD’s RotaTeq and GSK’s Rotarix
24 September 2010
GlaxoSmithKline sues Roche/Genentech alleging Herceptin patent infringements; updates on Relovair Ph II development with Theravance
23 September 2010
UK’s NICE turns down PharmaMar’s Yondelis and GlaxoSmithKline’s Arzerra
20 September 2010
UK’s NICE turns down GlaxoSmithKline’s Revolade, as drugmaker and Neurocrine’s antidepressant fails in Ph II
15 September 2010
Asthma drug albuterol may also benefit patients with multiple sclerosis
15 September 2010
GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
9 September 2010
GlaxoSmithKline’s Avandia still available in UK, despite MHRA call for its suspension
7 September 2010
US FDA moves approval goalposts for GSK/Valeant’s ezogabine and Eisai’s eribulin; Abbott/Eisai’s Humira filed for additional indication in Japan
1 September 2010
European Medicines Agency to review GlaxoSmithKline’s flu vaccine Pandemrix for possible link with narcolepsy
31 August 2010
GlaxoSmithKline gets amended license for Cervarix; initiates Ph III study of shingles vaccine
26 August 2010
FDA's new safety controls for LABA-containing drugs will impact prescribing for the treatment of asthma
26 August 2010
New study finds little difference in cardiac risk for GlaxoSmithKline’s Avandia and Takeda’s Actos
25 August 2010
GlaxoSmithKline and partner Human Genome get US FDA priority review for Benlysta; GSK ups stake in Chinese vaccines JV
20 August 2010
ABPI advertising code breaches by ProStrakan, Cephalon UK and GlaxoSmithKline Consumer Healthcare
18 August 2010
GlaxoSmithKline gets US FDA warning on aseptic meningitis risk with seizure drug Lamictal; favored investment by UBS analyst
16 August 2010
GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019
10 August 2010
Vectura boosted by deal with GSK worth over $30 million upfront plus royalties; J&J unit buys rights to Acuform technology
6 August 2010
GlaxoSmithKline signs deal with Amplimmune worth more than $500 million for AMP-224 in cancer and other diseases
5 August 2010
GlaxoSmithKline pays $15 million to exercise option on Anacor’s novel antibiotic; and $5 million milestone to Isis Pharma
1 August 2010
ViiV Healthcare committed to Phase III development program for investigational once-daily HIV integrase inhibitor
22 July 2010
Following US and European approval, Amgen/GSK’s Prolia will garner sales of more than $500 million in 2019
7 July 2010
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
